On August 2nd, Gelonhui reported that ST Special Treat Pharmaceutical (600671.SH) recently received the 'Drug Re-Registration Approval Notice' issued and approved by the Zhejiang Provincial Drug Administration. 1. The main components of Pearl Brightening Eye Drops are pearl liquid and natural borneol. It is a colorless and clear liquid with a fragrant aroma. Its main functions are clearing heat and removing fire, nourishing liver and brightening eyes, used for visual fatigue and chronic conjunctivitis. 2. The main component of Ribavirin Eye Drops is ribavirin, whose chemical name is: 1-β-D furan nucleoside-1H-1.2.4-triazole-3-carboxamide; it is a colorless and clear liquid. It is mainly used to treat herpes simplex virus keratitis. 3. Oral solution of Inosine is a water solution of inosine with the addition of stevioside or sucrose. Inosine participates in cellular energy metabolism and protein synthesis in the body, improves the activity of relevant metabolic enzymes, improves liver function, and promotes the recovery of damaged liver. It is mainly used for adjuvant treatment of acute and chronic hepatitis.
The acquisition of the 'Drug Re-Registration Approval Notice' for the above medicines ensures the stability and continuity of the company's pharmaceutical production and sales qualifications, and has positive implications for the company's future production, sales, and promotion. Currently, the company is working on process optimization research for the production line of Pearl Brightening Eye Drops, has initiated GMP compliance inspection pre-preparation work, and the final resumption time will be based on the approval time of the drug regulatory agency.